Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Cabometyx
nivolumab with cabozantinib · Bristol Myers Squibb / Exelixis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line therapy for patients with advanced renal cell carcinoma.
LAMPGEN ANALYSIS
Why it matters
The decision pairs immune checkpoint blockade with a multikinase inhibitor in the first-line setting.
What research teams should watch
Track oral cabozantinib adherence and infusion timing together, with attribution procedures for overlapping toxicities.
PRIMARY RECORDS